Cara taps Korean firm as first licensee for its lead analgesic
This article was originally published in Scrip
The US venture Cara Therapeutics has struck the first licensing deal for its lead product candidate CR845, allying with Chong Kun Dang Pharmaceutical (CKD) for the development and marketing of the analgesic in South Korea.
You may also be interested in...
With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.
Amid simmering regional geopolitical tensions, speakers at a recent conference highlighted the multiple benefits of conducting clinical trials in Taiwan, while pointing to what more could be done to improve the local ecosystem.